| Literature DB >> 21237172 |
Benjamin M Hutchins1, Stephanie A Kazane, Karin Staflin, Jane S Forsyth, Brunhilde Felding-Habermann, Peter G Schultz, Vaughn V Smider.
Abstract
Immunoconjugates and multispecific antibodies are rapidly emerging as highly potent experimental therapeutics against cancer. We have developed a method to incorporate an unnatural amino acid, p-acetylphenylalanine (pAcPhe) into an antibody antigen binding fragment (Fab) targeting HER2 (human epidermal growth factor receptor 2), allowing site-specific labeling without disrupting antigen binding. Expression levels of the pAcPhe-containing proteins were comparable to that of wild-type protein in shake-flask and fermentation preparations. The pAcPhe-Fabs were labeled by reaction with hydroxylamine dye and biotin species to produce well-defined, singly conjugated Fabs. We then coupled a hydroxylamine biotin to the pAcPhe-Fab and demonstrated controlled assembly of Fabs in the presence of the tetrameric biotin-binding protein, NeutrAvidin. The position of Fab biotinylation dictates the geometry of multimer assembly, producing unique multimeric Fab structures. These assembled Fab multimers differentially attenuate Her2 phosphorylation in breast cancer cells that overexpress the Her2 receptor. Thus, an encoded unnatural amino acid produces a chemical "handle" by which immunoconjugates and multimers can be engineered.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21237172 PMCID: PMC4278757 DOI: 10.1016/j.jmb.2011.01.011
Source DB: PubMed Journal: J Mol Biol ISSN: 0022-2836 Impact factor: 5.469